Aptevo Therapeutics (APVO) Invested Capital (2015 - 2022)

Aptevo Therapeutics has reported Invested Capital for 8 years, with the latest figure at $2.0 million in Q4 2022.

• Quarterly Invested Capital fell 82.86% year-over-year to $2.0 million in Q4 2022, while the trailing twelve-month figure through Sep 2023 was $2.0 million (down 88.68% YoY) and the FY2022 annual result came in at $2.0 million, down 82.86% from the prior year.
• Invested Capital held at $2.0 million in Q4 2022 per APVO's latest filing, from $2.0 million in the prior quarter.
• Over five years, Invested Capital peaked at $19.9 million in Q4 2019 and troughed at $2.0 million in Q1 2022.
• A 5-year average of $8.1 million and a median of $5.3 million in 2018 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2021 and 2022: Invested Capital soared 133.34% in 2021, then plunged 82.86% in 2022.
• Over 5 years, Invested Capital stood at $4.2 million in 2018, then soared by 376.67% to $19.9 million in 2019, then slumped by 74.83% to $5.0 million in 2020, then jumped by 133.34% to $11.7 million in 2021, then slumped by 82.86% to $2.0 million in 2022.
• According to Business Quant data, Invested Capital over the past three periods registered $2.0 million, $2.0 million, and $2.0 million for Q4 2022, Q3 2022, and Q2 2022 respectively.